| Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States | Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States. | NCT01722669 |
| Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease | A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease | NCT04514510 |
| Isoquercetin in Sickle Cell Anemia | Single-arm Phase 2 Study of Oral Isoquercetin in Sickle Cell Disease | NCT04474626 |
| Impact of isoQUercetin and Aspirin on Platelet Function | The Impact of Isoquercetin and Aspirin on Platelet Function | NCT02866448 |
| Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial | Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial | NCT02552888 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial | NCT02446795 |
| Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19 | An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19) | NCT04536090 |
| Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19 | A Randomized, Open-labelled and Controlled Clinical Trial to Investigate the Clinical Efficacy of Isoquercetin in the Treatment of Mild-to-moderate Hospitalised COVID-19 Patients | NCT04733651 |
| The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3) | NCT06861088 |
| Cancer Associated Thrombosis and Isoquercetin (CATIQ) | Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients. | NCT02195232 |
| Effect of a food-derived polyphenols supplement on plasma uric acid and other metabolic markers in healthy subjects | Effect of a food-derived isoquercitrin supplement on plasma uric acid and other metabolic markers: A randomised, double-blinded, placebo-controlled, cross-over trial in healthy adults | ACTRN12624000681550 |
| Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients. | A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients with Moderate and Severe COVID-19 | EUCTR2020-001635-27-FR |
